Acetaminophen - ASD/ADHD

This docket consolidates claims alleging that prenatal acetaminophen use is associated with an increased risk of autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD) in children, centralized before Judge Denise L. Cote in the Southern District of New York in October 2022. With 58 actions pending against 722 total filed, the docket has moved through the large majority of its original filing population, a decline of this magnitude in a pharmaceutical products-liability MDL typically reflecting a significant general-causation ruling or comparable dispositive development that narrowed which claims could proceed.

For a funder, this attrition pattern is the central fact to underwrite around. A docket that has shrunk from 722 to 58 pending actions is signaling that the general-causation theory connecting prenatal acetaminophen exposure to ASD or ADHD has faced a serious test in this proceeding, and any remaining claim needs to be evaluated against whatever legal or evidentiary standard determined which of the original claims could continue. That is a fundamentally different diligence exercise than evaluating a claim in a docket where causation remains an open, untested question.

There is no medical-lien component in the traditional sense here, since these are developmental-disability claims tied to a child's diagnosis and associated long-term care and therapy costs rather than acute injury treatment, though those long-term care costs can still be a relevant recovery-offset consideration. Given the sharply reduced and still-uncertain claim population, Criterica Capital's mass tort finance line should be applied here through careful individual-claim underwriting rather than portfolio-scale assumptions, and a structural brief on this docket's causation history is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.